Novo Nordisk ($NVO) in Free Fall: A Decade-Defining Opportunity or the End of the GLP-1 Era?
On February 3, 2026, Novo Nordisk ($NVO) shares plunged 14% following the release of its 2025 annual results. Despite robust sales of DKK 309.1B (+10% CER), Wall Street was spooked by a 2026 guidance projecting a 5% to 13% decline in adjusted operating profit. This contraction is driven by U.S. pricing pressures and a $4.2B […]





